A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2
Latest Information Update: 01 Aug 2024
At a glance
- Drugs XMT-2056 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Mersana Therapeutics
- 28 Feb 2024 Planned number of patients changed from 171 to 162.
- 28 Feb 2024 Planned End Date changed from 1 Nov 2025 to 1 Apr 2027.
- 28 Feb 2024 Planned primary completion date changed from 1 Nov 2025 to 1 Apr 2027.